Hansa raises $121 million in oversubscribed placement

10 July 2020

Swedish firm Hansa Biopharma (Nasdaq Stockholm: HNSA) is 1.1 billion Swedish kronor ($121 million) better off after completing a share placement.

The proceeds will be used to continue the development and expansion of the company’s R&D pipeline as well as to fund the potential launch and commercialization of imlifidase in kidney transplantation.

Søren Tulstrup, president and chief executive of Hansa, said: ”Based on the positive opinion on imlifidase for kidney transplant adopted by the CHMP of the European Medicines Agency a few weeks ago, we are now preparing for a potential launch in Europe later this year while also taking important steps forward in our efforts to build a highly valuable pipeline of drug candidates targeting serious rare diseases across multiple indication universes, including the agreement announced just last week with Sarepta Therapeutics (Nasdaq: SRPT) focused on enabling gene therapy in patients with Duchenne muscular dystrophy and Limb-girdle muscular dystrophy.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK